In a study, radical prostatectomy for men with Gleason 8-10 prostate cancer and low PSA levels was associated with a lower death risk compared with external beam radiation therapy with or without brachytherapy.
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
In a study, radiation delivered to the primary prostate tumor in men with metastatic castration-resistant prostate cancer was associated with a 74% decreased risk of death from any cause.
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
Patients younger than age 60 with Gleason 8-10 disease who had upfront surgery versus radiation therapy had a 63% lower risk of prostate cancer-specific mortality.
A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.
New multidisciplinary guideline for early-stage prostate cancer developed by 3 professional societies.
The 3-year survival rate was 81% for patients who underwent EBRT plus standard care vs 73% for those who had standard care alone.
